FIG. 1A



Tumor volume (mm3)
2000
1500
1000
500
0
0
5
10
15
20
25
Days
No Treatment
10mpk Antibody
+0.2mpk Example 36
5mpk Antibody
+0.1mpk Example 36
2.5mpk Antibody
+0.05mpk Example 36
1.25mpk Antibody
+0.025mpk Example 36

FIG. 1B



Compound Concentration, ng/mL
1000
100
10
1
0.1
0.01
0
50
100
150
Time, Hours

FIG. 1C



Analysis of Blood
Analysis of Tumor
%Cd11b+/Ly6CHi of CD45+/CD3-
15
10
5
0
No Treatment
10mpk Ab/0.2mpk Example 36
5mpk Ab/0.1mpk Example 36
2.5mpk Ab/0.05mpk Example 36
1.25mpk Ab/0.025mpk Example 36

FIG. 2A



No CD4/CD8 depletion
Antibody Control
No CD4/CD8 depletion
Example 36+Platform Antibody
Tumor volume (mm3)
1500
1000
500
0
0
5
10
15
Day

FIG. 2B



CD4/CD8 depletion
Antibody Control
CD4/CD8 depletion
Example 36 +Platform Antibody
Tumor volume (mm3)
2500
2000
1500
1000
500
0
0
5
10
15
Day

FIG. 3A



Compound Concentration, ng/mL
1000
100
10
0
24
48
72
96
120
144
168
Time points (h)
Codosed
Sequential Dosing- 0.5hour separation
Sequential Dosing - 2hour separation
Sequentail Dosing - 24hour separation

FIG. 3B



CD11b+/Ly6CHi %of CD45+
0.5
0.4
0.3
0.2
0.1
0.0

FIG. 4



Compound Concentration, ng/mL
1000
100
10
1
0
50
100
150
200
Time, Hours
Molar Ratio of
Small Molecule:Antibody
1:1
1.5:1
2:1
3:1
6:1

FIG. 5



Compound Concentration, ng/mL
1000
100
10
1
0.1
0
50
100
150
200
Time, Hours
Molar Ratio of
Small Molecule to Antibody
1:1
2:1
4:1
8:1
8:0

FIG. 6A



Compound Concentration, ng/mL
1000
100
10
1
0
24
48
Time, Hours
+ 10mpk Antibody IV
2mpk Example 36, PO
10mpk Example 36, PO
50mpk Example 36, PO
2mpk Example 36 , PO BID
50mpk Example 36, PO

FIG. 6B



%Cd11b+/Ly6CHi of CD45+/CD3-
0.5
0.4
0.3
0.2
0.1
0.0

FIG. 7A



Delivery of Cotinine to Group 2 animals
Compound Concentration, nM
10^3
10^2
10^1
10^0
10^{-1}
ex vivo EC_{50}
0
24
48
72
96
120
144
168
Time, Hours
Group 1: 10mpk Antibody +0.1mpk Example 36
Group 2: 10mpk Antibody +0.1mpk Example 36

FIG. 7B



Relative Target Cell Level
300
200
100
0
48
72
96
120
168
Time, Hours
Vehicle Control
48hour Depletion Status
Group 1
Group 2

FIG. 8A



No Treatment
Antibody Alone
Antibody+Example 36
CD4
CD14

FIG. 8B



No Treatment
Antibody Alone
Antibody + Example 36
Percent CD8+ T cells Divided
15
10
5
0
41%
67%
209%
Cells:Beads = 1:1
Cells:Beads = 2:1
Cells:Beads = 4:1

FIG. 9A



Compound Concentration, ng/mL
10000
1000
100
10
1
0.1
0
100
200
300
400
500
Time, Hours
50mpk Cotinine Antibody + 0.7mpk Example 1
10mpk Cotinine Antibody +0.14mpk Example 1
2mpk Cotinine Antibody +0.028mpk Example 1 (dosed at t=0 and 168hrs)

FIG. 9B



Depletion of Target Cells
Number CD14+CD16- (x10^3cells/mL)
200
150
100
50
0
0
200
400
600
Time, Hours
Vehicle control
50mpk Cotinine Antibody + 0.7mpk Example 1
10mpk Cotinine Antibody +0.14mpk Example 1
2mpk Cotinine Antibody +0.028mpk Example 1 (dosed at t=0 and 168hrs)

FIG. 10A




FIG. 10B




FIG. 11A

Healthy donor- PBMC depletion




FIG. 11B

Bladder Cancer Patient- PBMC Depletion




FIG. 12


Current Technology
Target Cell
Antibody
Effector Cell
Controlled Immune Response
CyTaC Platform
Binds target cell
Binds antibody
CyTaC (NCE)
Platform Antibody